Mid-career investigator award in allogeneic adoptive immunotherapy

描述（由申请人提供）：波特博士的主要职业重点是通过创新的细胞免疫疗法应用于癌症的POR。本申请描述了异体细胞治疗的研究计划，以及指导初级研究人员进行POR的详细建议。研究目标是利用重要的科学发现和临床前模型来产生新颖、有效和安全的同种异体细胞疗法来治疗癌症。该申请旨在支持专门的时间来加强个人临床和转化研究，指导几位杰出的初级临床科学家在POR和职业发展方面，将科学合作与创新的临床研究项目结合起来，并专注于个人职业和项目发展。每位学员将获得直接指导、支持和监督；将与每个学员和实验室小组进行定期会议，并与整个计划进行月度会议。将建立一个研究诊所，以最大限度地发挥研究潜力和指导机会。波特博士将与每位学员合作，确保成功参与POR，并将监督临床前研究设计、方案制定、患者护理、数据展示和手稿准备。他将向他们提供意见和协助，以确定资助机会，并准备拨款申请。他将协助他们进行合作和建立网络，这对职业发展、建立地区和国家声誉、促进独立思考和学术发展至关重要。通过这项奖励，一些项目将完成，其他项目将由PI或学员开发和发起。每个项目都与癌症治疗直接相关。PI将有机会通过与细胞免疫治疗相关的会议、会议和扩大教育来进行额外的知识追求。这些努力将带来思想、能量、资源和合作的注入，将细胞和分子免疫学的快速发展与临床移植治疗联系起来，并将该小组联合起来，成为过继免疫治疗的首要转化研究项目。这将为培养下一代领先的临床研究人员提供一个理想的框架，对职业发展至关重要，扩大我们将新疗法快速转化为临床试验的能力，迅速获得额外的独立资金，并迅速推进细胞免疫疗法在癌症中的应用。

DESCRIPTION (provided by applicant): Dr. Porter's major career focus has been on POR for cancer through innovative applications of cellular immunotherapy. This application describes both a research program in allogeneic cellular therapy, and a detailed proposal for mentoring junior investigators in POR. The research goals are to use important scientific discoveries and preclinical models to generate novel, effective and safe allogeneic cellular therapies to treat cancer. This application is to support dedicated time to enhance personal clinical and translational research, to mentor several exceptional junior clinical scientists in POR and career development, to integrate scientific collaborations with the innovative clinical research program, and to concentrate on personal career and program development. Each mentee will receive direct mentoring, support, and supervision; regular meetings will be set with each mentee and lab group, and monthly meetings will occur with the full program. A research clinic will be established to maximize research potential and mentoring opportunities. Dr. Porter will work with each mentee to insure successful participation in POR and will oversee pre-clinical research design, protocol development, patient care, data presentation and manuscript preparation. He will advise and assist them to identify funding opportunities and with preparation of grant applications. He will assist them with collaborations and networking vital for career development, building of regional and national reputations, and to foster independent thought and academic growth. Through this award, several projects will be completed, and others developed and initiated by the PI or a trainee. Each project is directly relevant to the treatment for cancer. The PI will have opportunity for additional intellectual pursuits through meetings, conferences, and expanded education relevant to cellular immunotherapy. These efforts will result in an infusion of ideas, energy, resources, and collaborations that will link the rapid advances in cellular and molecular immunology to clinical transplantation therapy and unite the group into a premier translational research program in adoptive immunotherapy. This will provide an ideal framework to train the next generation of leading clinical investigators, be vital for career development, expand our ability to rapidly translate novel therapies into clinical trials, lead quickly to additional independent funding, and rapidly advance the application of cellular immunotherapy for cancer.